These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

251 related articles for article (PubMed ID: 21134077)

  • 101. Overexpression of CKS2 is associated with a poor prognosis and promotes cell proliferation and invasion in breast cancer.
    Huang N; Wu Z; Hong H; Wang X; Yang F; Li H
    Mol Med Rep; 2019 Jun; 19(6):4761-4769. PubMed ID: 30957190
    [TBL] [Abstract][Full Text] [Related]  

  • 102. FBXW7 and USP7 regulate CCDC6 turnover during the cell cycle and affect cancer drugs susceptibility in NSCLC.
    Morra F; Luise C; Merolla F; Poser I; Visconti R; Ilardi G; Paladino S; Inuzuka H; Guggino G; Monaco R; Colecchia D; Monaco G; Cerrato A; Chiariello M; Denning K; Claudio PP; Staibano S; Celetti A
    Oncotarget; 2015 May; 6(14):12697-709. PubMed ID: 25885523
    [TBL] [Abstract][Full Text] [Related]  

  • 103. Prognostic and therapeutic value of mitochondrial serine hydroxyl-methyltransferase 2 as a breast cancer biomarker.
    Zhang L; Chen Z; Xue D; Zhang Q; Liu X; Luh F; Hong L; Zhang H; Pan F; Liu Y; Chu P; Zheng S; Lou G; Yen Y
    Oncol Rep; 2016 Nov; 36(5):2489-2500. PubMed ID: 27666119
    [TBL] [Abstract][Full Text] [Related]  

  • 104. Poor prognosis in cholangiocarcinoma patients with low FBXW7 expression is improved by chemotherapy.
    Ishii N; Araki K; Yokobori T; Watanabe A; Tsukagoshi M; Kubo N; Suzuki H; Saito F; Altan B; Hosouchi Y; Shirabe K; Kuwano H
    Oncol Lett; 2017 May; 13(5):3653-3661. PubMed ID: 28521468
    [TBL] [Abstract][Full Text] [Related]  

  • 105. Clinical implications of β-catenin protein expression in breast cancer.
    Wang Z; Zhang H; Hou J; Niu J; Ma Z; Zhao H; Liu C
    Int J Clin Exp Pathol; 2015; 8(11):14989-94. PubMed ID: 26823833
    [TBL] [Abstract][Full Text] [Related]  

  • 106. Expression and prognostic role of SGTA in human breast carcinoma correlates with tumor cell proliferation.
    Zhu T; Ji Z; Xu C; Peng Z; Gu L; Zhang R; Liu Y
    J Mol Histol; 2014 Dec; 45(6):665-77. PubMed ID: 25027991
    [TBL] [Abstract][Full Text] [Related]  

  • 107. High expression of ubiquitin carboxy-terminal hydrolase-L1 and -L3 mRNA predicts early recurrence in patients with invasive breast cancer.
    Miyoshi Y; Nakayama S; Torikoshi Y; Tanaka S; Ishihara H; Taguchi T; Tamaki Y; Noguchi S
    Cancer Sci; 2006 Jun; 97(6):523-9. PubMed ID: 16734731
    [TBL] [Abstract][Full Text] [Related]  

  • 108. Identification of aberrantly expressed F-box proteins in squamous-cell lung carcinoma.
    Wang K; Qu X; Liu S; Yang X; Bie F; Wang Y; Huang C; Du J
    J Cancer Res Clin Oncol; 2018 Aug; 144(8):1509-1521. PubMed ID: 29728763
    [TBL] [Abstract][Full Text] [Related]  

  • 109. PKCalpha expression is a marker for breast cancer aggressiveness.
    Lønne GK; Cornmark L; Zahirovic IO; Landberg G; Jirström K; Larsson C
    Mol Cancer; 2010 Apr; 9():76. PubMed ID: 20398285
    [TBL] [Abstract][Full Text] [Related]  

  • 110. Expression Profile and Prognostic Values of Mini-Chromosome Maintenance Families (MCMs) in Breast Cancer.
    Cheng L; Tan Z; Huang Z; Pan Y; Zhang W; Wang J
    Med Sci Monit; 2020 Aug; 26():e923673. PubMed ID: 32830194
    [TBL] [Abstract][Full Text] [Related]  

  • 111. Cyclins in breast cancer: too much of a good thing.
    Enders GH
    Breast Cancer Res; 2002; 4(4):145-7. PubMed ID: 12100739
    [TBL] [Abstract][Full Text] [Related]  

  • 112. Downregulated PIRH2 Can Decrease the Proliferation of Breast Cancer Cells.
    Yang S; Chen Y; Sun F; Ni Q; Wang H; Huang Y; Zhang C; Liu K; Wang S; Qiu J; Xu Z; Hua L; He Z
    Arch Med Res; 2016 Apr; 47(3):186-95. PubMed ID: 27393961
    [TBL] [Abstract][Full Text] [Related]  

  • 113. Rhomboid domain containing 2 (RHBDD2): a novel cancer-related gene over-expressed in breast cancer.
    Abba MC; Lacunza E; Nunez MI; Colussi A; Isla-Larrain M; Segal-Eiras A; Croce MV; Aldaz CM
    Biochim Biophys Acta; 2009 Oct; 1792(10):988-97. PubMed ID: 19616622
    [TBL] [Abstract][Full Text] [Related]  

  • 114. Clinical significance of NDRG3 in patients with breast cancer.
    Estiar MA; Zare AA; Esmaeili R; Farahmand L; Fazilaty H; Jafari D; Samadi T; Majidzadeh-A K
    Future Oncol; 2017 May; 13(11):961-969. PubMed ID: 28326836
    [TBL] [Abstract][Full Text] [Related]  

  • 115. Ubiquitin-conjugating enzyme 2C (UBE2C) is a poor prognostic biomarker in invasive breast cancer.
    Kariri Y; Toss MS; Alsaleem M; Elsharawy KA; Joseph C; Mongan NP; Green AR; Rakha EA
    Breast Cancer Res Treat; 2022 Apr; 192(3):529-539. PubMed ID: 35124721
    [TBL] [Abstract][Full Text] [Related]  

  • 116. The expression of CXCL13 and its relation to unfavorable clinical characteristics in young breast cancer.
    Chen L; Huang Z; Yao G; Lyu X; Li J; Hu X; Cai Y; Li W; Li X; Ye C
    J Transl Med; 2015 May; 13():168. PubMed ID: 25990390
    [TBL] [Abstract][Full Text] [Related]  

  • 117. Upregulation of centromere protein M promotes tumorigenesis: A potential predictive target for cancer in humans.
    Liu Y; Yu W; Ren P; Zhang T
    Mol Med Rep; 2020 Nov; 22(5):3922-3934. PubMed ID: 33000180
    [TBL] [Abstract][Full Text] [Related]  

  • 118. RNF126 as a Biomarker of a Poor Prognosis in Invasive Breast Cancer and CHEK1 Inhibitor Efficacy in Breast Cancer Cells.
    Yang X; Pan Y; Qiu Z; Du Z; Zhang Y; Fa P; Gorityala S; Ma S; Li S; Chen C; Wang H; Xu Y; Yan C; Ruth K; Ma Z; Zhang J
    Clin Cancer Res; 2018 Apr; 24(7):1629-1643. PubMed ID: 29326282
    [No Abstract]   [Full Text] [Related]  

  • 119. OGFOD1 is required for breast cancer cell proliferation and is associated with poor prognosis in breast cancer.
    Kim JH; Lee SM; Lee JH; Chun S; Kang BH; Kwak S; Roe JS; Kim TW; Kim H; Kim WH; Cho EJ; Youn HD
    Oncotarget; 2015 Aug; 6(23):19528-41. PubMed ID: 25909288
    [TBL] [Abstract][Full Text] [Related]  

  • 120. Reduced FBXW7 expression in pancreatic cancer correlates with poor prognosis and chemotherapeutic resistance via accumulation of MCL1.
    Ishii N; Araki K; Yokobori T; Gantumur D; Yamanaka T; Altan B; Tsukagoshi M; Igarashi T; Watanabe A; Kubo N; Hosouchi Y; Kuwano H; Shirabe K
    Oncotarget; 2017 Dec; 8(68):112636-112646. PubMed ID: 29348852
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.